COMMENT Primary results from the Phase 3 study of LMTX were not significant, but a significant treatment effect was reported in a subgroup of approximately 15 percent of ACTIVE patients who were not taking concomitant ACHEI therapy. Unfortunately, the analysis ...
CONFERENCE COVERAGE SERIES In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period. Held July 24 to 28 in Toronto, the Alzheimer’s Association International Conference showcased a field in transformation. At the clinical level, groups from Europe, North America, and Japan ...
CONFERENCE COVERAGE 2016-07-29 Conference Coverage Results of the eagerly awaited Phase 3 clinical trial of LMTM, a derivative of the dye methylene blue, generated consternation at the Alzheimer’s Association International Conference 2016, held July 22-28 in Toronto. Speaking to a ...
C2N DiagnosticsSaint Louis, United States
RESEARCH NEWS 2016-07-29 Research News Tau proteins come in two varieties in the brain, depending on how neurons splice the mRNA. The four-repeat (4R) form underlies several tauopathies, including frontotemporal dementia, but researchers have struggled to directly compare its ...
PAPER Adams SJ, DeTure MA, McBride M, Dickson DW, Petrucelli L20520830
PAPER Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, Liefaard L, Lourbakos A, Morgan A, Nakielny J, Quarcoo N, Ricotti V, Rolfe K, Servais L, Wardell C, Wilson R, Wright P, Kraus JE
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.Lancet Neurol. 2014 Oct;13(10):987-96. Epub 2014 Sep 7 PubMed: 25209738
Banking (32 yrs); U.S. Army (25 yrs, active & reserves)Bryan, United States
Universidad Complutense de MadridMadrid, Spain
University of BarcelonaSpain
PAPER Xu S, Panikker P, Iqbal S, Elefant F27454757
PAPER Werner P, Doron II
Alzheimer's disease and the law: positive and negative consequences of structural stigma and labeling in the legal system.Aging Ment Health. 2016 Jul 27;:1-8. PubMed: 27463564
PAPER Kravchick DO, Karpova A, Hrdinka M, Lopez-Rojas J, Iacobas S, Carbonell AU, Iacobas DA, Kreutz MR, Jordan BA
Synaptonuclear messenger PRR7 inhibits c-Jun ubiquitination and regulates NMDA-mediated excitotoxicity.EMBO J. 2016 Jul 25; PubMed: 27458189
PAPER Lethin C, Renom-Guiteras A, Zwakhalen S, Soto-Martin M, Saks K, Zabalegui A, Challis DJ, Nilsson C, Karlsson S
Psychological well-being over time among informal caregivers caring for persons with dementia living at home.Aging Ment Health. 2016 Jul 27;:1-9. PubMed: 27463390
No filters selected